EDIT · XBRL financial data

Editas Medicine financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (EDIT's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	91	26	20	78	32	41
Research and development	158	143	175	178	199	90
General and administrative	68	76	71	70	72	50
Total operating expenses	226	219	246	247	283	201
Operating income (loss)	(135)	(193)	(226)	(169)	(251)	(160)
Interest expense	—	—	—	—	0	2
Other income (expense)	16	(2)	1	(2)	(0)	(2)
Income tax expense (benefit)	—	0	0	0	0	0
Net income (loss)	(116)	(193)	(220)	(153)	(237)	(160)
Earnings per share, basic USD per share	(1.98)	(2.85)	(3.21)	(2.02)	(2.88)	(1.80)
Earnings per share, diluted USD per share	(1.98)	(2.83)	(3.21)	(2.02)	(2.88)	(1.80)
Weighted average shares, basic millions of shares	59	68	69	76	82	89
Weighted average shares, diluted millions of shares	59	68	69	76	82	89

Fiscal years (EDIT's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	140	204	142	124	132	147
Marketable securities	262	296	203	199	138	0
Marketable securities, non-current	110	120	93	104	0	—
Prepaid and other current assets	11	7	7	8	3	2
Total current assets	419	507	357	341	289	164
Property and equipment, net	14	17	16	12	14	4
Right-of-use asset	25	26	44	34	33	16
Total assets	573	677	514	499	342	187
Accounts payable	6	5	10	8	5	3
Accrued liabilities	24	20	31	35	46	33
Current portion of long-term debt	—	—	—	0	5	5
Total current liabilities	58	47	60	63	77	46
Long-term debt	—	—	—	0	52	54
Lease liability, non-current	19	16	33	24	20	12
Total liabilities	179	124	154	150	207	159
Accumulated deficit	(665)	(858)	(1,078)	(1,231)	(1,468)	(1,629)
Total stockholders' equity	394	554	361	349	134	27
Total liabilities and equity	573	677	514	499	342	187
Common shares outstanding (cover page) millions of shares	67	69	69	82	83	98

Fiscal years (EDIT's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(116)	(193)	(220)	(153)	(237)	(160)
Stock-based compensation	23	43	29	20	21	10
Net cash from operating activities	(180)	(164)	(177)	(132)	(210)	(165)
Purchases of property and equipment	7	8	4	5	9	1
Net cash from investing activities	(141)	(54)	114	(4)	162	139
Proceeds from issuing common stock	204	249	0	117	0	43
Net cash from financing activities	224	282	1	118	56	40
Net change in cash	(96)	64	(62)	(18)	8	14

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Editas Medicine	182	12	(30)*	153.6M	7.2 quarters	Q2 FY26 10-QJun 30, 2026
Merus	367	12	(85)*	75.8M	7.5 quarters	Q3 FY25 10-QSep 30, 2025
Palvella Therapeutics	188	not reported	(13)*	14.4M	19.5 quarters	Q2 FY26 10-QJun 30, 2026
Esperion Therapeutics	156	80	(28)	257.4M	5.6 quarters	Q1 FY26 10-QMar 31, 2026
Rezolute	11	not reported	(13)*	96.7M	8.2 quarters	Q4 FY26 10-KJun 30, 2026
Cardiff Oncology	9.2	0.1	(12)*	77.8M	2.9 quarters	Q2 FY26 10-QJun 30, 2026
Silence Therapeutics	72	0	1.5*	141.7M	—	Q2 FY26 10-QJun 30, 2026
Crescent Biopharma	172	0	(19)*	37.1M	8.8 quarters	Q2 FY26 10-QJun 30, 2026
Mersana Therapeutics	56	11	(3.2)*	5.0M	17.7 quarters	Q3 FY25 10-QSep 30, 2025

Not investment advice. Not affiliated with the U.S. SEC.